Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Satralizumab Biosimilar - Anti-IL6R mAb - Research Grade |
---|---|
Source | CAS 1535963-91-7 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Satralizumab,SA-237,IL6R,anti-IL6R |
Reference | PX-TA1407 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG2-kappa |
Clonality | Monoclonal Antibody |
Satralizumab is a humanized monoclonal antibody that targets human interleukin-6 (IL-6) receptors, similar to tocilizumab. Satralizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD). Increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased permeability of the blood-brain barrier are thought to be mediated by IL-6. Satralizumab is thought to block IL-6 receptors and, thereby, these inflammatory responses.
Immobilized CD126 Recombinant Protein (cat. No.PX-P4104) at 0.5µg/mL (100µL/well) can bind to Satralizumab Biosimilar - Anti-IL6R mAb (cat. No.PX-TA1407) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Related products
Reviews
Il n’y a pas encore d’avis.